Purpose
to enable developing country HPV vaccine manufacturers to access the monoclonals to assist in converting from in vivo potency testing to in vitro (mAb) potency testing, reducing COGS and increasing reliability of supply and delivery
Grantee
Division
Global Health
Date
NOVEMBER 2020
Region served
GLOBAL
Committed amount
$1,176,665
Grant topic
Vaccine Development
Duration (months)
37
Grantee location
Seattle, Washington, United States
Related work
More about our financials
Our work
Learn about where we work around the globe and the programs we’ve created to address urgent issues in global health, global development, and education.
How we work
We are focused on results. Those that can be measured. And those measured in ways beyond numbers.